Importance of serum concentration of adefovir for lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 8, 2010, Pages 3205-3211

  Mitsui, Fukiko ^a,b   Tsuge, Masataka ^a,b   Kimura, Takashi ^a,b   Kitamura, Shosuke ^a,b   Abe, Hiromi ^a,b   Saneto, Hiromi ^a,b   Kawaoka, Tomokazu ^a,b   Miki, Daiki ^a,b   Hatakeyama, Tsuyoshi ^a,b   Hiraga, Nobuhiko ^a,b   Imamura, Michio ^a,b   Kawakami, Yoshiiku ^a,b   Aikata, Hiroshi ^a,b   Takahashi, Shoichi ^a,b   Hayes, C Nelson ^a,b   Igarashi, Harue ^c   Morimoto, Kentaro ^c   Shimizu, Masao ^c   Chayama, Kazuaki ^a,b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c Development and Medical Affairs Division   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; CREATININE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; VIRUS REPLICATION;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 77955402520     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01372-09     Document Type: Article

References (40)

1. Allen, M. I., M. Deslauriers, C. W. Andrews, G. A. Tipples, K. A. Walters, D. L. Tyrrell, N. Brown, and L. D. Condreay. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677.
2. Angus, P., R. Vaughan, S. Xiong, H. Yang, W. Delaney, C. Gibbs, C. Brosgart, D. Colledge, R. Edwards, A. Ayres, A. Bartholomeusz, and S. Locarnini. 2003. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125:292-297. (Pubitemid 36929407)
3. Balzarini, J., Z. Hao, P. Herdewijn, D. G. Johns, and E. De Clercq. 1991. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl) adenine, a potent anti-human immunodeficiency virus compound. Proc. Natl. Acad. Sci. U. S. A. 88:1499-1503.
4. Bozdayi, A. M., C. P. Eyigun, A. R. Turkyilmaz, I. Y. Avci, A. Pahsa, and C. Yurdaydin. 2004. A novel pattern (sW195a) in surface gene of HBV DNA due to YSDD (L180M plus M204S) mutation selected during lamivudine therapy and successful treatment with adefovir dipivoxil. J. Clin. Virol. 31:76-77.
5. Bozdayi, A. M., O. Uzunalimoǧlu, A. R. Türkyilmaz, N. Aslan, O. Sezgin, T. Sahin, G. Bozdayi, K. Cinar, S. B. Pai, R. Pai, H. Bozkaya, S. Karayaçin, C. Yurdaydin, and R. F. Schinazi. 2003. YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J. Viral Hepat. 10:256-265.
6. Bruix, J., and J. M. Llovet. 2003. Hepatitis B virus and hepatocellular carcinoma. J. Hepatol 39(Suppl. 1):S59-S63.
7. Buti, M., R. Jardi, M. Cotrina, F. Rodriguez-Frias, R. Esteban, and J. Guardia. 1998. Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. J. Hepatol. 28:510-513. (Pubitemid 28133557)
8. Chang, T. T., C. L. Lai, R. N. Chien, R. Guan, S. G. Lim, C. M. Lee, K. Y. Ng, G. J. Nicholls, J. C. Dent, and N. W. Leung. 2004. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 19:1276-1282.
9. Chayama, K., Y. Suzuki, M. Kobayashi, M. Kobayashi, A. Tsubota, M. Hashimoto, Y. Miyano, H. Koike, M. Kobayashi, I. Koida, Y. Arase, S. Saitoh, N. Murashima, K. Ikeda, and H. Kumada. 1998. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27:1711-1716. (Pubitemid 28264699)
10. Cihlar, T., D. C. Lin, J. B. Pritchard, M. D. Fuller, D. B. Mendel, and D. H. Sweet. 1999. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol. Pharmacol. 56:570-580.
11. Conjeevaram, H. S., and A. S. Lok. 2003. Management of chronic hepatitis B. J. Hepatol 38(Suppl. 1):S90-S103.
12. Delaney, W. E., IV, H. Yang, C. E. Westland, K. Das, E. Arnold, C. S. Gibbs, M. D. Miller, and S. Xiong. 2003. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol. 77:11833-11841.
13. Fung, S. K., P. Andreone, S. H. Han, K. Rajender Reddy, A. Regev, E. B. Keeffe, M. Hussain, C. Cursaro, P. Richtmyer, J. A. Marrero, and A. S. Lok. 2005. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J. Hepatol. 43:937-943.
14. Fung, S. K., H. B. Chae, R. J. Fontana, H. Conjeevaram, J. Marrero, K. Oberhelman, M. Hussain, and A. S. Lok. 2006. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. 44:283-290. (Pubitemid 43069209)
15. Ganem, D., and A. M. Prince. 2004. Hepatitis B virus infection - natural history and consequences. N. Engl. J. Med. 350:1118-1129.
16. Ghany, M., and T. J. Liang. 2007. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 132:1574-1585.
17. Hadziyannis, S. J., N. C. Tassopoulos, E. J. Heathcote, T. T. Chang, G. Kitis, M. Rizzetto, P. Marcellin, S. G. Lim, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, C. L. Brosgart, and the Adefovir Dipivoxil 438 Study Group. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348:800-807.
18. Ijaz, S., C. Arnold, S. Dervisevic, J. Mechurova, N. Tatman, R. S. Tedder, and N. V. Naoumov. 2008. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. J. Med. Virol. 80:1160-1170.
19. Jardi, R., M. Buti, F. Rodriguez-Frias, M. Cotrina, X. Costa, C. Pascual, R. Esteban, and J. Guardia. 1999. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J. Virol. Methods 83:181-187.
20. Kobayashi, M., F. Suzuki, N. Akuta, Y. Suzuki, Y. Arase, K. Ikeda, T. Hosaka, H. Sezaki, M. Kobayashi, S. Iwasaki, J. Sato, S. Watahiki, Y. Miyakawa, and H. Kumada. 2006. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotype A, B, and C. J. Med. Virol. 78:1276-1283. (Pubitemid 44387512)
21. Lai, C. L., J. Dienstag, E. Schiff, N. W. Leung, M. Atkins, C. Hunt, N. Brown, M. Woessner, R. Boehme, and L. Condreay. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36:687-696.
22. Lampertico, P., M. Viganò, E. Manenti, M. Iavarone, E. Sablon, and M. Colombo. 2007. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133:1445-1451.
23. Lee, Y. S., D. J. Suh, Y. S. Lim, S. W. Jung, K. M. Kim, H. C. Lee, Y. H. Chung, Y. S. Lee, W. Yoo, and S. O. Kim. 2006. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43:1385-1391. (Pubitemid 43980117)
24. Leung, N. W., C. L. Lai, T. T. Chang, R. Guan, C. M. Lee, K. Y. Ng, S. G. Lim, P. C. Wu, J. C. Dent, S. Edmundson, L. D. Condreay, R. N. Chien, and the Asia Hepatitis Lamivudine Study Group. 2001. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33:1527-1532.
25. Marcellin, P., T. T. Chang, S. G. Lim, M. J. Tong, W. Sievert, M. L. Shiffman, L. Jeffers, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, C. L. Brosgart, and the Adefovir Dipivoxil 437 Study Group. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348:808-816.
26. Melegari, M., P. P. Scaglioni, and J. R. Wands. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
27. Perrillo, R., E. Schiff, E. Yoshida, A. Statler, K. Hirsch, T. Wright, K. Gutfreund, P. Lamy, and A. Murray. 2000. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32:129-134. (Pubitemid 30432377)
28. Peters, M. G., H. Hann Hw, P. Martin, E. J. Heathcote, P. Buggisch, R. Rubin, M. Bourliere, K. Kowdley, C. Trepo, D. Gray Df, M. Sullivan, K. Kleber, R. Ebrahimi, S. Xiong, and C. L. Brosgart. 2004. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126:91-101.
29. Robbins, B. L., J. Greenhaw, M. C. Connelly, and A. Fridland. 1995. Metabolic pathways for activation of the antiviral agent 9-(2- phosphonylmethoxyethyl) adenine in human lymphoid cells. Antimicrob. Agents Chemother. 39:2304-2308.
30. Schildgen, O., H. Sirma, A. Funk, C. Olotu, U. C. Wend, H. Hartmann, M. Helm, J. K. Rockstroh, W. R. Willems, H. Will, and W. H. Gerlich. 2006. Variant of hepatitis B virus with primary resistance to adefovir. N. Engl. J. Med. 354:1807-1812.
31. Severini, A., X. Y. Liu, J. S. Wilson, and D. L. Tyrrell. 1995. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2′, 3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 39:1430-1435.
32. Suzuki, F., A. Tsubota, Y. Arase, Y. Suzuki, N. Akuta, T. Hosaka, T. Someya, M. Kobayashi, S. Saitoh, K. Ikeda, M. Kobayashi, M. Matsuda, J. Satoh, K. Takagi, and H. Kumada. 2003. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 46:182-189.
33. Suzuki, Y., H. Kumada, K. Ikeda, K. Chayama, Y. Arase, S. Saitoh, A. Tsubota, M. Kobayashi, M. Koike, N. Ogawa, and K. Tanikawa. 1999. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J. Hepatol. 30:743-748. (Pubitemid 29248970)
34. Uwai, Y., H. Ida, Y. Tsuji, T. Katsura, and K. Inui. 2007. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm. Res. 24:811-815.
35. Villet, S., C. Pichoud, J. P. Villeneuve, C. Trépo, and F. Zoulim. 2006. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 131:1253-1261. (Pubitemid 44515103)
36. Wright, T. L., and J. Y. Lau. 1993. Clinical aspects of hepatitis B virus infection. Lancet 342:1340-1344.
37. Xiong, X., C. Flores, H. Yang, J. J. Toole, and C. S. Gibbs. 1998. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28:1669-1673.
38. Yatsuji, H., N. Hiraga, N. Mori, T. Hatakeyama, M. Tsuge, M. Imamura, S. Takahashi, Y. Fujimoto, H. Ochi, H. Abe, T. Maekawa, F. Suzuki, H. Kumada, and K. Chayama. 2007. Successful treatment of an entecavir-resistant hepatitis B virus variant. J. Med. Virol. 79:1811-1817.
39. Yatsuji, H., C. Noguchi, N. Hiraga, N. Mori, M. Tsuge, M. Imamura, S. Takahashi, E. Iwao, Y. Fujimoto, H. Ochi, H. Abe, T. Maekawa, C. Tateno, K. Yoshizato, F. Suzuki, H. Kumada, and K. Chayama. 2006. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob. Agents Chemother. 50:3867-3874.
40. Yatsuji, H., F. Suzuki, H. Sezaki, N. Akuta, Y. Suzuki, Y. Kawamura, T. Hosaka, M. Kobayashi, S. Saitoh, Y. Arase, K. Ikeda, S. Watahiki, S. Iwasaki, M. Kobayashi, and H. Kumada. 2008. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J. Hepatol. 48:923-931.